A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee
Purpose
The goal of this clinical trial is to learn if a single knee injection of different doses (Dose A and Dose B) of an investigation product PCRX-201, following steroid pretreatment, is safe and tolerable in male of female patients 45 to 80 years old with osteoarthritis of the knee. It will also learn how the body reacts to the PCRX-201 injection and how effective the treatment is. Researchers will compare Dose A and Dose B of PCRX-201 versus placebo from Week 1 through Week 52 to assess adverse events. Researchers will also explore how PCRX-201 may impact knee pain and joint function over time. Participants will be asked to - Visit the clinic for pretreatment and drug administration - Visit the clinic for checkups and tests: 1. Screening through Week 52: intially weekly, bi-weekly, later monthly 2. Week 53 through Week 260 (Year 5): 8 visits throughout the period
Condition
- Osteoarthritis (OA) of the Knee
Eligibility
- Eligible Ages
- Between 45 Years and 80 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Subjects must be willing and able to comply with the study procedures and visit schedule and able to follow verbal and written instructions. - Subjects must be male or female and 45 to 80 years old, inclusive, at Screening. - Subjects must exhibit symptoms associated with osteoarthritis of the index knee for ≥12 months before Screening (subject self-reporting is acceptable). - Subjects must have index knee pain for >15 days over the last month before Screening (subject self-reporting is acceptable). - Subjects must have failed 2 or more therapies: Restricted physical activity as per Osteoarthritis Research Society International (OARSI) core level recommendation, ie, "structured land-based exercise" (this may include physical therapy), and failure of an additional type of conservative therapy for OA of the index knee, eg, nonselective NSAIDs or COX-2 inhibitors, in the past 12 months. - Subjects must have a body mass index (BMI) ≤40 kg/m2 at Screening. - Subjects must have an index knee examination indicating the index knee and the intended injection site area are free of any signs of local or joint infection at Baseline. - Subjects must have an index knee Average Daily Knee Pain (NRS) between ≥5.0 and ≤9.0 at Screening and Baseline. - Sexually active subjects of child-bearing potential (SOCBP) and their partners must agree to use effective birth control while in the study - Subjects must have active synovitis in the index knee as determined by ultrasound Doppler. - Subjects must exhibit American College of Rheumatology Criteria (clinical and radiological) for osteoarthritis as follows: 1. Knee pain 2. At least 1 of the following: i. Age >50 years ii. Morning stiffness <30 minutes iii. Crepitus on knee motion c. Osteophytes - Subjects must have K-L Grade 2, 3, or 4 in the index knee based on X-rays performed during Screening and confirmed by trained radiographers at a central facility before enrollment - Subjects need to show the presence of moderate or severe synovitis based on 11-point synovitis score using contrast-enhanced MRI
Exclusion Criteria
- Subjects have any current or prior diagnosis of autoimmune connective tissue disorders, secondary OA conditions, benign synovial tumors, gout/pseudogout, reactive arthritis, RA, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease. - Subjects have any active systemic or local infection, including infection of the index knee - Subjects are unable to undergo MRI with contrast MRI - Subjects with X-ray or MRI exclusionary events - Subjects have an unstable index knee joint (eg, torn anterior cruciate ligament) within 12 months of Screening - Subjects have used any approved or investigational IA drug/biologic in index knee within 6 months of Screening (eg, hyaluronic acid, platelet rich plasma, stem cells, prolotherapy, and amniotic fluid injection) - Subjects are receiving or have received any gene therapy treatment (eg, IL-1Ra) in the past 3 years - Subjects have used IA steroids ≤3 months before screening Other protocol-defined criteria apply
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Intervention Model Description
- In Part A (manufacturing process 1), subjects are randomized in a 1:1:1 ratio to Dose A , Dose B , or placebo, each with a predose IA steroid of methylprednisolone acetate. In Part B (manufacturing process 2), subjects are randomized in a 1:1:1 ratio to Dose A, Dose B, or placebo, each with a pre-dose IA steroid of methylprednisolone acetate.
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Part A Dose A |
Single Intra-Articular injection |
|
|
Placebo Comparator Part A, Placebo |
Single Intra-Articular injection |
|
|
Experimental Part B Dose A |
Single Intra-Articular injection |
|
|
Experimental Part B Dose B |
Single Intra-Articular injection |
|
|
Placebo Comparator Part B Placebo |
Part B Placebo |
|
|
Experimental Part A, Dose B |
Single Intra-Articular injection |
|
Recruiting Locations
Huntington Beach 5358705, California 5332921 92647
La Mesa 5363990, California 5332921 91942
West Hills 8030162, California 5332921 91307
Daytona Beach 4152872, Florida 4155751 32117
Oldsmar 4166936, Florida 4155751 34677-4681
West Palm Beach 4177887, Florida 4155751 33409
Winter Park 4178560, Florida 4155751 32789
Lincoln 5072006, Nebraska 5073708 68516
Las Vegas 5506956, Nevada 5509151 89109
Duncansville 5187508, Pennsylvania 6254927 16635
Charleston 4574324, South Carolina 4597040 29406
Columbia 4575352, South Carolina 4597040 29206
Dallas 4684888, Texas 4736286 75230
Lewisville 4706057, Texas 4736286 75057
More Details
- NCT ID
- NCT06884865
- Status
- Recruiting
- Sponsor
- Pacira Pharmaceuticals, Inc
Detailed Description
The study will consist of two parts, Part A and Part B, which will use PCRX-201 from two different manufacturing processes. A total of 135 eligible subjects, with painful OA of the index knee will be enrolled. Subjects will be randomly assigned to a treatment dose group, stratified by Kellgren-Lawrence (K-L) Grade, in both parts of the study. Enrollment of subjects with K-L Grade 4 will be capped at 4 subjects per dose group in Part A and 8 subjects per dose group in Part B. Enrollment of subjects with K-L Grade 2 or 3 will include a minimum of 4 subjects per Grade per dose group in Part A and a minimum of 8 subjects per Grade per dose group in Part B. This study does not require an equal number of subjects between K-L Grade 2 and 3. All eligible subjects will be pretreated with the same dose of methylprednisolone acetate (40 mg) on Day 1 immediately before treatment with PCRX-201 or placebo. Part A will enroll approximately 45 subjects into 3 dose groups (15 subjects in each treatment group, stratified by K-L Grade as noted above). Part B will enroll approximately 90 subjects into 3 groups (30 subjects in each treatment group, stratified by K-L Grade as noted above). Enrollment in Part B is dependent upon the availability of study drug developed with manufacturing process 2.